# EDGAR Filing Document

**Accession Number:** 0001231457
**File Stem:** 0001641172-25-022598
**Filing Date:** 2025-8
**Character Count:** 22042
**Document Hash:** b98207f4751758ea83ea7846712e69dc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-022598.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001641172-25-022598

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**EFFECTIVENESS DATE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENELUX Corp
- **CENTRAL INDEX KEY:** 0001231457
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289377
- **FILM NUMBER:** 251194940

**BUSINESS ADDRESS:**
- **STREET 1:** 2625 TOWNSGATE ROAD, SUITE 230
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91361
- **BUSINESS PHONE:** 805-267-9889

**MAIL ADDRESS:**
- **STREET 1:** 2625 TOWNSGATE ROAD, SUITE 230
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91361

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENELUX CORP
- **DATE OF NAME CHANGE:** 20030508

**As filed with the Securities and Exchange Commission on August 7, 2025**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER THE SECURITIES ACT OF 1933***

 ****

 ****

**GENELUX CORPORATION**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **77-0583529** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(I.R.S. Employer<br> Identification No.)** |
| **2625 Townsgate Road, Suite 230**<br> **Westlake Village, California 91361** | **91361** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Genelux Corporation 2023 Inducement Plan**

**(Full title of the plan)**

**Thomas Zindrick, J.D.**

**President and Chief Executive Officer**

**Genelux Corporation**

**2625 Townsgate Road, Suite 230**

**Westlake Village, California 91361**

**(805) 267-9889**

**(Name, address, and telephone number, including area code, of agent for service)**

***Copies to:***

 ****

**Jason L. Kent**

**Christine S. Kim**

**Cooley LLP**

**10265 Science Center Drive**

**San Diego, California 92121**

**(858) 550-6000**

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (the "**Registration Statement**") is being filed for the purpose of registering an additional 1,000,000 shares of common stock, par value $0.001 per share (the "**Common Stock**"), reserved and available for issuance under the 2023 Inducement Plan (the "***Inducement Plan***") of Genelux Corporation (the "**Registrant**").

Pursuant to General Instruction E of Form S-8, this Registration Statement incorporates by reference the contents of the registration statement on Form S-8 relating to the Inducement Plan filed by the Registrant with the Securities and Exchange Commission (the "**Commission**") on November 14, 2023 (File No. [333-275555](https://www.sec.gov/Archives/edgar/data/1231457/000149315223041350/forms-8.htm)).

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the "**Securities Act**"), and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents, which have been filed with the Commission by the Registrant, pursuant to the Securities Act, and the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), as applicable, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

(a) The
 Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on [March 28, 2025](https://www.sec.gov/Archives/edgar/data/1231457/000164117225001184/form10-k.htm) (as amended on [April 29, 2025](https://www.sec.gov/Archives/edgar/data/1231457/000164117225006650/form10-ka.htm)), which contains audited financial statements for the Registrant's latest fiscal year for
 which such statements have been filed;

(b) The
 Registrant's Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31,
 2025 and June 30, 2025, filed with the Commission on [May 6, 2025](https://www.sec.gov/Archives/edgar/data/1231457/000164117225008838/form10-q.htm) and [August 7, 2025](https://www.sec.gov/Archives/edgar/data/1231457/000164117225022583/form10-q.htm) , respectively;

(c) The
 Registrant's Current Reports on Form 8-K filed with the Commission on [February 3, 2025](https://www.sec.gov/Archives/edgar/data/1231457/000149315225004554/form8-k.htm) , [March 25, 2025](https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/form8-k.htm) and [March 25, 2025](https://www.sec.gov/Archives/edgar/data/1231457/000164117225000642/form8-k.htm) (other than the portions thereof which are furnished and
 not filed); and

(d) The
 description of the Registrant's Common Stock contained in the Registrant's Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1231457/000119312523013085/d526802d8a12b.htm) filed with
 the Commission on January 23, 2023 (File No. 001-41599) under Section 12(b) of the Exchange Act, including any amendments or reports
 filed for the purpose of updating such description, including [Exhibit 4.16](https://www.sec.gov/Archives/edgar/data/1231457/000164117225001184/ex4-16.htm) of the Registrant's Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1231457/000164117225001184/form10-k.htm) ,
 filed with the Commission on March 28, 2025.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

**Item 8. Exhibits.**

The exhibits to this Registration Statement are listed below:

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 4.1 | [Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-41599), filed with the Commission on January 30, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000119312523019058/d389604dex31.htm) |
| 4.2 | [Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-41599), filed with the Commission on January 30, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000119312523019058/d389604dex32.htm) |
| 4.3 | [Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on August 29, 2022).](https://www.sec.gov/Archives/edgar/data/1231457/000119312522232732/d300051dex41.htm) |
| 4.4 | [Investors' Rights Agreement, by and among the Registrant and AbbVie, Inc. and Aladar Szalay, Ph.D., dated January 2010 (incorporated herein by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).](https://www.sec.gov/Archives/edgar/data/1231457/000119312522181565/d300051dex42.htm) |
| 4.5 | [Form of Warrant to Purchase Common Stock issued to WDC Fund I, dated September 2020 (incorporated herein by reference to Exhibit 4.3 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).](https://www.sec.gov/Archives/edgar/data/1231457/000119312522181565/d300051dex43.htm) |
| 4.6 | [Form of Umbrella Agreement Regarding Family Investments (incorporated herein by reference to Exhibit 4.5 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).](https://www.sec.gov/Archives/edgar/data/1231457/000119312522181565/d300051dex45.htm) |
| 4.7 | [Form of Convertible Note Purchase Agreement under the Umbrella Agreement (incorporated herein by reference to Exhibit 4.6 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the Commission on June 24, 2022).](https://www.sec.gov/Archives/edgar/data/1231457/000119312522181565/d300051dex46.htm) |
| 4.8 | [Form of Representative's Warrant (incorporated herein by reference to Exhibit 4.7 to the Registrant's Current Report on Form 8-K (File No. 001-41599), filed with the Commission on January 30, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000119312522246569/d300051dex11.htm) |
| 4.9 | [Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.8 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-41599), filed with the Commission on May 15, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000149315223016832/ex4-8.htm) |
| 4.10 | [Letter Agreement Amending the Umbrella Agreements, by and among the Registrant and Existing Noteholders dated April 4, 2023 (incorporated by reference to Exhibit 4.10 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-41599), filed with the Commission on May 15, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000149315223016832/ex4-10.htm) |
| 4.11 | [Form of Warrant to Purchase Common Stock issued on July 28, 2023 in connection with Converted Convertible Notes Payable (incorporated by reference to Exhibit 4.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-41599), filed with the Commission on August 14, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000149315223027998/ex4-3.htm) |
| 4.12 | [Form of Warrant to Purchase Common Stock issued on August 1, 2023 in connection with Converted Convertible Notes Payable. (incorporated by reference to Exhibit 4.4 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-41599), filed with the SEC on August 14, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000149315223027998/ex4-4.htm) |
| 4.13 | [Form of Indenture (incorporated by reference to Exhibit 4.14 to the Registrant's Registration Statement on Form S-3 (File No. 333-276847), filed with the Commission on February 2, 2024.](https://www.sec.gov/Archives/edgar/data/1231457/000149315224004774/ex4-14.htm) |
| 4.14 | [Form of Common Stock Warrant Agreement and Warrant Certificate (incorporated by reference to Exhibit 4.17 to the Registrant's Registration Statement on Form S-3 (File No. 333-276847), filed with the Commission on February 2, 2024.](https://www.sec.gov/Archives/edgar/data/1231457/000149315224004774/ex4-17.htm) |
| 4.15 | [Form of Preferred Stock Warrant Agreement and Warrant Certificate (incorporated by reference to Exhibit 4.18 to the Registrant's Registration Statement on Form S-3 (File No. 333-276847), filed with the Commission on February 2, 2024).](https://www.sec.gov/Archives/edgar/data/1231457/000149315224004774/ex4-18.htm) |

---

---

| | |
|:---|:---|
| 4.16 | [Form of Debt Securities Warrant Agreement and Warrant Certificate (incorporated by reference to Exhibit 4.19 to the Registrant's Registration Statement on Form S-3 (File No. 333-276847), filed with the Commission on February 2, 2024).](https://www.sec.gov/Archives/edgar/data/1231457/000149315224004774/ex4-19.htm) |
| 4.17 | [Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-41599), filed with the Commission on May 24, 2024).](https://www.sec.gov/Archives/edgar/data/1231457/000149315224021265/ex4-1.htm) |
| 5.1\* | [Opinion of Cooley LLP.](ex5-1.htm) |
| 23.1\* | [Consent of Weinberg & Company, P.A., independent registered public accounting firm.](ex23-1.htm) |
| 23.2\* | [Consent of Cooley LLP (included in Exhibit 5.1).](ex5-1.htm) |
| 24.1\* | [Power of Attorney (included on the signature page hereto).](#poa_001) |
| 99.1 | [Genelux Corporation 2023 Inducement Plan (incorporated by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-41599), filed with the Commission on November 14, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000149315223041151/ex10-2.htm) |
| 99.2 | [Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement for Executive Officers under the Genelux Corporation 2023 Inducement Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-41599), filed with the Commission on November 14, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000149315223041151/ex10-3.htm) |
| 99.3 | [Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement for Non-Executives under the Genelux Corporation 2023 Inducement Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-41599), filed with the Commission on November 14, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000149315223041151/ex10-4.htm) |
| 99.4 | [Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise for Executive Officers under the Genelux Corporation 2023 Inducement Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-41599), filed with the Commission on November 14, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000149315223041151/ex10-5.htm) |
| 99.5 | [Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise for Non-Executives under the Genelux Corporation 2023 Inducement Plan (incorporated by reference to Exhibit 10.6 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-41599), filed with the Commission on November 14, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000149315223041151/ex10-6.htm) |
| 107\* | [Filing Fee Table.](ex107.htm) |

---

\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Westlake Village, State of California, on August 7, 2025.

---

| | |
|:---|:---|
| **GENELUX CORPORATION** | **GENELUX CORPORATION** |
| By: | */s/ Thomas Zindrick, J.D.* |
|  | Thomas Zindrick, J.D. |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Thomas Zindrick, J.D. and Matthew Pulisic as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Thomas Zindrick, J.D.*<br>| &nbsp;&nbsp;President, Chief Executive Officer and Chairman of the Board<br>| August 7, 2025 |
| Thomas Zindrick, J.D. | (*Principal Executive Officer*) |  |
| */s/ Matthew Pulisic*<br>| &nbsp;&nbsp;Chief Financial Officer<br>| August 7, 2025 |
| Matthew Pulisic | (*Principal Financial and Accounting Officer*) |  |
| */s/ Mary Mirabelli*<br>| &nbsp;&nbsp;Director | August 7, 2025 |
| Mary Mirabelli |  |  |
| */s/ John Smither* | &nbsp;&nbsp;Director | August 7, 2025 |
| John Smither |  |  |
| */s/ James L. Tyree*<br>| &nbsp;&nbsp;Director | August 7, 2025 |
| James L. Tyree |  |  |
| */s/ John Thomas, Ph.D.*<br>| &nbsp;&nbsp;Director | August 7, 2025 |
| John Thomas, Ph.D. |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

![](ex5-1_002.jpg)

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 pertaining to the 2023 Inducement Plan of Genelux Corporation of our report dated March 28, 2025, (which report contains an explanatory paragraph describing conditions that raise substantial doubt about Genelux Corporation's ability to continue as a going concern), relating to the financial statements of Genelux Corporation as of December 31, 2024 and 2023, which appear in Genelux Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission.

/s/Weinberg & Company, P.A.

Los Angeles, California

August 7, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Table**

**Form S-8**

(Form Type)

**Genelux Corporation**

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

****

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security Type** | **Security**<br> **Class Title** | **Fee<br> Calculation**<br> **Rule** | **Amount<br> Registered** | **Proposed<br> Maximum<br> Offering<br> Price Per<br> Share** | **Maximum<br> Aggregate**<br> **Offering**<br> **Price** | **Fee**<br> **Rate** | **Amount of<br> Registration<br> Fee** |
| (1) | Equity | Common Stock, $0.001 par value per share, reserved for issuance pursuant to the Inducement Plan | Other | 1000000 | $3.44 | $3440000 | 0.00015310 | $527 |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $3440000 |  | $527 |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $527 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the
"Securities Act"), this Registration Statement shall also cover additional shares of the Registrant's common stock,
par value $0.001 per share ("Common Stock"), which become issuable under the Registrant's 2023 Inducement Plan (the
"Inducement Plan") by reason of any stock split, stock dividend, recapitalization, or other similar transaction. This estimate
is made pursuant to Rule 457(h) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price
per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on August 1, 2025 as
reported on the Nasdaq Capital Market. Represents the number of shares of Common Stock available for issuance under the Inducement Plan
being registered hereunder.